CTLA4 and hepatocellular carcinoma: Zhou et al. proposed a treatment protocol involving the administration of 6 mg/kg of AK104 (a PD-1/CTLA-4 BSAB) in combination with lenvatinib as a first-line therapy for patients diagnosed with unresectable advanced HCC.